Nectin Therapeutics
Jerusalem
About Nectin Therapeutics
Nectin Therapeutics is developing novel monoclonal antibodies directed towards members of the Nectin family of receptors and ligands that have major roles in the immune checkpoint mechanisms relevant for cancer immune therapy. These novel antibodies are developed for the treatment of solid and hematological malignancies.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $46.4M
- Last round: Series Unknown (May 2024)
- Website: nectintx.com
- Phone: +972 5 4424 7524
Industries & Categories
Biotechnology, Life Science, Oncology
Social Profiles
Canonical: https://fsome.com/organization/nectin-therapeutics-48413 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.